Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids

1. A composition for delivering at least one gene editing molecule to a cell, the composition comprising:

a micelle assembled from a plurality of triblock copolymers, wherein each triblock copolymer having at least one hydrophobic block, at least one hydrophilic block, and at least one poly(L-histidine) block,

wherein:

the at least one poly(L-histidine) block complexes with the at least one gene editing molecule;

the at least one poly(L-histidine) block is capable of a pH dependent release of the at least one gene editing molecule;

the at least one hydrophilic block comprises poly(ethylene oxide) and the at least one hydrophobic block comprises poly(lactic acid); and

wherein the at least one gene editing molecule comprises one or more of a nucleic acid encoding for a protein, wherein the protein is selected from the group consisting of a transposase, a nuclease and an integrase;

wherein the molar ratio of triblock copolymers to the at least one gene editing molecule is about 20:1.

2. The composition of claim 1 , wherein the nuclease is selected from the group comprising:

a CRISPR associated protein 9 (Cas9);

a type IIS restriction enzyme;

a transcription activator-like effector nuclease (TALEN); and

a zinc finger nuclease (ZFN).

3. The composition of claim 1 , wherein the at least one gene editing molecule further comprises one or more transposable elements.

4. The composition of claim 3 , wherein the one or more transposable elements comprise a piggyBac transposon, a Sleeping Beauty transposon or a LINE-1 (L1) transposon.

5. The composition of claim 1 , wherein the protein is a transposase.

6. A kit, comprising:

a pharmaceutical composition comprising the composition of claim 1 ; and

an implement for administering the pharmaceutical composition intravenously, via inhalation, topically, per rectum, per the vagina, transdermally, subcutaneously, intraperitoneally, intrathecally, intramuscularly or orally.

7. A composition for delivering at least one gene editing molecule to a cell, the composition comprising:

a micelle assembled from a plurality of triblock copolymers, wherein each triblock copolymer having at least one hydrophobic block, at least one hydrophilic block, and at least one poly(L-histidine) block,

wherein:

the at least one poly(L-histidine) block complexes with the at least one gene editing molecule;

the at least one poly(L-histidine) block is capable of a pH dependent release of the at least one gene editing molecule;

the at least one hydrophilic block comprises poly(ethylene oxide) and the at least one hydrophobic block comprises poly(lactic acid); and

wherein the at least one gene editing molecule comprises one or more of a protein, wherein the protein is selected from the group consisting of a transposase, a nuclease and an integrase;

wherein the molar ratio of triblock copolymers to the at least one gene editing molecule is about 2:3.

8. The composition of claim 7 , wherein the nuclease is selected from the group comprising:

a CRISPR associated protein 9 (Cas9);

a type IIS restriction enzyme;

a transcription activator-like effector nuclease (TALEN); and

a zinc finger nuclease (ZFN).

9. The composition of claim 7 , wherein the at least one gene editing molecule further comprises one or more transposable elements.

10. The composition of claim 9 , wherein the one or more transposable elements comprise a piggyBac transposon, a Sleeping Beauty transposon or a LINE- 1 (L 1 ) transposon.

11. The composition of claim 7 , wherein the protein is a transposase.

12. A kit, comprising:

a pharmaceutical composition comprising the composition of claim 7 ; and

an implement for administering the pharmaceutical composition intravenously, via inhalation, topically, per rectum, per the vagina, transdermally, subcutaneously, intraperitoneally, intrathecally, intramuscularly or orally.